-
Mashup Score: 1Program Guide – ASCO Meeting Program Guide - 2 year(s) ago
AuthorsBinod DhakalMedical College of Wisconsin, Milwaukee, WIBinod Dhakal, Shruti Sharma, Svetlana Shchegrova, Minu Maninder, Meenakshi Malhotra, Himanshu Sethi, Bernhard Zimmermann, Paul R. Billings, Alexey Aleshin, Parameswaran HariOrganizationsMedical College of Wisconsin, Milwaukee, WI, Natera, Inc., San Carlos, CA, Omicia, Oakland, CAAbstract DisclosuresResearch FundingNo funding…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials. - 2 year(s) ago
e13588 Background: Pre-screening for clinical trials is becoming more challenging as inclusion/exclusion criteria becomes increasingly complex. Oncology precision medicine provides an exciting opportunity to simplify this process and quickly match patients with trials by leveraging machine learning technology. The Tempus TIME Trial site network matches patients to relevant, open, and recruiting…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials [May 28, 2021] Sachse et al. #ASCO21 Abstract e13588 https://t.co/EpwreOUmM8 #PrecisionMedicine #ClinicalTrials #ctsm https://t.co/MdBAkWpj2x
-
-
Mashup Score: 0Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials. - 2 year(s) ago
e13588 Background: Pre-screening for clinical trials is becoming more challenging as inclusion/exclusion criteria becomes increasingly complex. Oncology precision medicine provides an exciting opportunity to simplify this process and quickly match patients with trials by leveraging machine learning technology. The Tempus TIME Trial site network matches patients to relevant, open, and recruiting…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials [May 28, 2021] Sachse et al. #ASCO21 Abstract e13588 https://t.co/EpwreOUmM8 #PrecisionMedicine #ClinicalTrials #ctsm https://t.co/RPsu8dQRtu
-
-
Mashup Score: 1Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials. - 2 year(s) ago
e13588 Background: Pre-screening for clinical trials is becoming more challenging as inclusion/exclusion criteria becomes increasingly complex. Oncology precision medicine provides an exciting opportunity to simplify this process and quickly match patients with trials by leveraging machine learning technology. The Tempus TIME Trial site network matches patients to relevant, open, and recruiting…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials [May 28, 2021] Sachse et al. #ASCO21 Abstract e13588 https://t.co/EpwreOUmM8 #PrecisionMedicine #ClinicalTrials #ctsm https://t.co/Q1R9UBdfa5
-
-
Mashup Score: 1Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials. - 2 year(s) ago
e13588 Background: Pre-screening for clinical trials is becoming more challenging as inclusion/exclusion criteria becomes increasingly complex. Oncology precision medicine provides an exciting opportunity to simplify this process and quickly match patients with trials by leveraging machine learning technology. The Tempus TIME Trial site network matches patients to relevant, open, and recruiting…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials [May 28, 2021] Sachse et al. #ASCO21 Abstract e13588 https://t.co/EpwreOCLny #PrecisionMedicine #ClinicalTrials #ctsm https://t.co/2vqSYmPoOi
-
-
Mashup Score: 0Program Guide – ASCO Meeting Program Guide - 2 year(s) ago
DetailsCitationJ Clin Oncol 39, 2021 (suppl 15; abstr 9105)AuthorsEyob ale TadesseAurora Cancer Care, Advocate Aurora Health, Milwaukee, WIEyob ale Tadesse, Kayla Heslin, Mohamed Hendawi, Luke Peterson, Frank M. Wolf, Thomas D. Brown, Michael A. ThompsonOrganizationsAurora Cancer Care, Advocate Aurora Health, Milwaukee, WI, Advocate Aurora Health, Milwaukee, WI, Syapse INC, San Francisco, CA,…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Genomic markers associated with hyperprogression in patients with lung cancer treated with immune checkpoint inhibitors - Tadesse et al. #ASCO21 Abs 9105 https://t.co/IpuygzczQA #PrecisionMedicine #ImmunoOnc https://t.co/d06oGRKQTM
-
-
Mashup Score: 2Program Guide – ASCO Meeting Program Guide - 2 year(s) ago
AuthorsMohamed HendawiAurora Cancer Care, Advocate Aurora Health, Milwaukee, WIMohamed Hendawi, Luke Peterson, Eyob ale Tadesse, Frank M. Wolf, Thomas D. Brown, Michael A. ThompsonOrganizationsAurora Cancer Care, Advocate Aurora Health, Milwaukee, WI, Syapse INC, San Francisco, CA, Syapse, San Francisco, CAAbstract DisclosuresResearch FundingNo funding receivedNone Background: Patients (pts)…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Myocarditis as a rare, yet serious adverse event associated w/ immune checkpoint inhibitors in patients w/ NSCLC: Case series from a large community-based cancer center - Hendawi et al. @Aurora_Cancer @Syapse #ASCO21 Abs e21047 https://t.co/OFrRxoP2kE #irAE #ImmunoOnc #CardioOnc
-
-
Mashup Score: 0Should We Teach Cost-Effectiveness of Cancer-Related Therapies in Oncology Training? - 2 year(s) ago
With the current pace of progress in cancer care, urgent implementation of cost-effectiveness training curriculum in fellowship training programs will be indispensable, shares Dr. Samer Al Hadidi.
Source: ASCO ConnectionCategories: Hem/Oncs, Latest HeadlinesTweet-
We tried last year to present a cost effectiveness 101 educational talk #ASCO21 . Unfortunately this didn’t work out. We (@inas_md @amarkelkar & myself) are 1 year older & will try again maybe next year😁 @ASCO #ASCO23 ?! Check why IMO this is important 👇 https://t.co/2nQdZVl1p2 https://t.co/y1nyimVDLx
-
-
Mashup Score: 5Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies - 2 year(s) ago
This cross-sectional study evaluates the representation of racial and ethnic minority groups in breast, prostate, lung, and colorectal cancer studies with a focus on precision medicine objectives.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Throwback to #ASCO21 when our team led by @Aldrighetti_C virtually presented this, now 📃 at ➡️ https://t.co/DkyBuU0YNj ⭐️excited to be at #ASCO22 this yr presenting ➡️ https://t.co/3oFRAb3IKq Looking forward to networking/establishing collabs! (+mtg all Twitter friends IRL😉) https://t.co/05j2PA5iRw
-
-
Mashup Score: 0TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) × CD3 BISPECIFIC... by Niels WJC van de Donk - 2 year(s) ago
EHA Library; WJC van de Donk N. Jun 9 2021; 324601;
Source: library.ehaweb.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
#EHA21 oral presentation Same as #ASCO21 ➡️ https://t.co/pIIsj9ks8a ⭐️pts (n=156) ⭐️cutoff:2/2021 ⭐️ORR:65%, CR or better:~30%, DOR:NR, AEs👇 https://t.co/tLVTYLA3LF
-
Personalized, ctDNA analysis to detect minimal residual disease & identify Pts at high risk of relapse w/ multiple myeloma - @bhemato et al. @Phari #ASCO21 Abstract 8029 https://t.co/OyywlExqea #mmsm #mmMRD n=28 BM flow vs @NateraOncology Signatera MRD @ 3 months post-AHCT https://t.co/fu9J0c659X